Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2021 | SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL

Ian Flinn • 9 Dec 2021
ASH 2021
Hodgkin Lymphoma Lymphoma Antibodies Brentuximab vedotin Dacarbazine Doxorubicin Nivolumab
SGN35-027

Existing trials have shown brentuximab vedotin, a CD30-directed antibody-drug conjugate (ADC), with vinblastine, as well as nivolumab monotherapy to have good efficacy and safety profiles in patients with Hodgkin lymphoma. Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, provides an overview of the trial design and rationale of the open-label, Phase II SGN35-027 trial (NCT03646123), which will investigate brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in patients with newly diagnosed patients with early-stage Hodgkin lymphoma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Ian Flinn

Unanswered questions in frontline CLL treatment
0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
Umbralisib and ublituximab in patients with CLL and comorbidities
1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
Debulking strategies in CLL before venetoclax therapy
2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021
Safety and efficacy of rapcabtagene autoleucel (YTB323), a CAR T-cell therapy, in r/r DLBCL
3:43
Safety and efficacy of rapcabtagene autoleucel (YTB323), a CAR T-cell therapy, in r/r DLBCL
Ian Flinn • 9 Dec 2021

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals